China's Leading CRO WuXi Looks To Utilize Manufacturing Capacity With Telaprevir
This article was originally published in PharmAsia News
SHANGHAI - Leading Chinese contract research organization WuXi PharmaTech Co., Ltd. recorded a strong quarter with revenue up 16% over the same period last year to $93.6 million, and the company is readying itself for big increases in its manufacturing business thanks to large-scale contracts generated from discovery deals
You may also be interested in...
After Another Strong Quarter, WuXi Aims To Become Backbone Of China’s Life Science Industry: China Earnings Roundup (Part 1)
Despite a macroeconomic slowdown, China’s leading CRO reported another strong quarter due to increasing demand for R&D services from both international and domestic companies.
WuXi PharmaTech Attempts To Tame The Tiger Of Labor Inflation As It Feels The Pinch In 2012: China Earnings Roundup (Part 2)
WuXi invests heavily to offer differentiated services with premium prices to counter growing labor costs in China; moves more facilities inland for cheaper labor.
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.